Niue vs Peru: Statin use vs. average non-HDL cholesterol levels

Niue
3.4
in 2018
Peru
3.4
in 2018
Niue rank
75th
Peru rank
75th

Statin use vs. average non-HDL cholesterol levels over time

  • Niue
  • Peru
01234198019992018

How they compare

Niue currently reports 3.4 against 3.4 in Peru, a difference of 0.

Across all 39 years both countries report, Peru has been ahead every year.

Niue ranks 75th and Peru ranks 75th of 191 countries.

Peru has averaged higher in every one of the 4 decades both report.

Head to head by decade

Decade Niue Peru Difference Ahead
1980s 3.37 3.59 0.22 Peru
1990s 3.5 3.6 0.1 Peru
2000s 3.45 3.51 0.06 Peru
2010s 3.4 3.44 0.0444 Peru

Averages of every year both report within each decade.

Frequently asked questions

Which has higher statin use vs. average non-hdl cholesterol levels, Niue or Peru?
Niue, at 3.4 against 3.4 in Peru as of 2018.
What is the difference in statin use vs. average non-hdl cholesterol levels between Niue and Peru?
0, with Niue ahead.
How many years of comparable data are there for Niue and Peru?
39 years are reported by both, from 1980 to 2018.
How do Niue and Peru rank globally for statin use vs. average non-hdl cholesterol levels?
Niue ranks 75th and Peru ranks 75th of 191 countries.
Where does this data come from?
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.

Individual pages

About this data

Indicator
Statin use vs. average non-HDL cholesterol levels
Source
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
191 places, 7,449 data points, 1980–2018
Last refreshed

The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.